Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States — Food and Drug Administration & Novo Nordisk

17 shared events · Importance 4 · Last updated Sep 24, 2026

Importance
4
Shared Events
17
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
75
Regulatory
United States — Food and Drug Administration: US regulator that has not added a NAION warning to GLP-1 labels but is conducting an ongoing review through its Sentinel Initiative. Its eventual decision could reshape labeling and prescribing for the entire drug class.
Novo Nordisk: Primary defendant facing more than 90 lawsuits in New Jersey state court and separate federal cases over NAION claims tied to Ozempic and Wegovy. The litigation and potential label changes pose a material liability and reputational risk to its GLP-1 franchise.
Sep 21, 2026 · 20 articles
65
Regulatory
United States — Food and Drug Administration: The FDA has been cracking down on compounded GLP-1s; the study supports the need for further regulatory action.
Novo Nordisk: Novo Nordisk's Wegovy is one of the GLP-1 drugs being prescribed via telehealth; the study may lead to stricter oversight that could affect sales.
Jul 07, 2026 · 6 articles
62
Tech
United States — Food and Drug Administration: Its Adverse Event Reporting System supplied 13 of the 15 cases reviewed, placing the agency at the center of any potential label or safety review of GLP-1 medications.
Novo Nordisk: Maker of semaglutide-based Ozempic, Wegovy and Rybelsus, the drugs most frequently linked to the reported Wernicke encephalopathy cases. The negative safety headline could pressure its shares and invite regulatory scrutiny, though causation is unproven.
Sep 11, 2026 · 6 articles
55
Business
United States — Food and Drug Administration: Approved Tirzepatide for cardiovascular risk reduction; regulatory decisions on Retatrutide and Orforglipron are key catalysts.
Novo Nordisk: Main competitor; its sales fell and it launched Semaglutide pill to contest oral GLP-1 market, but its valuation lags Lilly significantly.
Aug 23, 2026 · 6 articles
52
Domestic
United States — Food and Drug Administration: The FDA approved semaglutide for diabetes and weight management but not for alcohol use disorder; the trial may lead to a new indication.
Novo Nordisk: Novo Nordisk's semaglutide is the drug being tested; positive results could expand its approved uses and market, though the trial is early-stage.
Jul 30, 2026 · 6 articles
49
Regulatory
United States — Food and Drug Administration: The FDA granted priority review to Agios' sNDA, setting a November 1 PDUFA date; its decision will determine mitapivat's market access.
Novo Nordisk: Novo Nordisk is a competitor developing a rival oral PK activator; its positive trial data adds competitive pressure on Agios.
Jul 07, 2026 · 6 articles
49
Tech
United States — Food and Drug Administration: The agency approved semaglutide for adolescents aged 12 to 17, and the study's findings may inform future labeling or monitoring guidance.
Novo Nordisk: As maker of semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda), the company faces potential reputational and regulatory pressure from findings on pediatric nutritional deficiencies.
Sep 21, 2026 · 7 articles
42
Business
United States — Food and Drug Administration: The FDA is the regulatory body reviewing Novo Nordisk's Mim8 submission. Its decision will influence the adoption of new hemophilia treatments and the demand for associated diagnostic assays.
Novo Nordisk: Novo Nordisk's submission of Mim8 to the FDA is a key driver of interest in Precision BioLogic's assay. The event indirectly supports Novo Nordisk's hemophilia treatment pipeline by ensuring accurate diagnostic testing.
Aug 27, 2026 · 6 articles
33
Business
United States — Food and Drug Administration: Approved the tirzepatide label expansion into cardiovascular risk on August 28, 2026, and its pending review of retatrutide is a key 2027 catalyst for Lilly.
Novo Nordisk: Its post-Wegovy strategy update disappointed, sending shares down 7.93% in a single session and adding competitive noise that weighed on Lilly sentiment. Consensus target implies only about 10-17% upside with analysts skewing Hold.
Sep 14, 2026 · 6 articles
0
Business
Novo Nordisk: Novo Nordisk launched its Wegovy pill in the United States, aiming to attract new consumers and regain market share in the competitive weight-loss drug market. This launch is expected to boost its fortunes after previous profit warnings and sliding shares.
Jan 05, 2026 · 7 articles
0
Regulatory
Novo Nordisk: Novo Nordisk received United States — Food and Drug Administration approval for its Wegovy pill, gaining an edge in the obesity treatment market over Eli Lilly and Company. The company expects the pill to be available within weeks, with a starting dose of $149 per month.
Dec 22, 2025 · 23 articles
0
Regulatory
Feb 07, 2026 · 6 articles
0
Business
Feb 05, 2026 · 6 articles
0
Business
Apr 01, 2026 · 7 articles
0
International
Apr 01, 2026 · 16 articles
0
Tech
Mar 10, 2026 · 13 articles
0
Tech
Novo Nordisk: Novo Nordisk announced positive topline results from its HIBISCUS phase 3 trial for etavopivat, a drug for sickle cell disease, which is expected to lead to regulatory submission and potential market approval, significantly boosting the company's pipeline and market position.
Apr 20, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States — Food and Drug Administration and Novo Nordisk interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.